

Edgar Filing: SEATTLE GENETICS INC /WA - Form SC 13G

SEATTLE GENETICS INC /WA  
Form SC 13G  
August 10, 2011

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. )\*

Seattle Genetics Incorporated  
(Name of Issuer)

Common Stock  
(Title of Class of Securities)

812578102  
(CUSIP Number)

July 29, 2011  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: SEATTLE GENETICS INC /WA - Form SC 13G

CUSIP: 812578102

Page 1 of 9

1 NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
Capital Group International, Inc.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a)

3 SEC USE ONLY

(b)

4 CITIZENSHIP OR PLACE OF ORGANIZATION

California

5 SOLE VOTING POWER

11,003,130

6 SHARED VOTING POWER

NUMBER OF  
SHARES  
BENEFICIA  
L  
LY OWNED BY

NONE

7 SOLE DISPOSITIVE POWER

EACH  
REPORTING  
PERSON  
WITH:

12,519,805

8 SHARED DISPOSITIVE POWER

NONE

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

12,519,805  
13d-4

Beneficial ownership disclaimed pursuant to Rule

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

11.0%

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

HC

Edgar Filing: SEATTLE GENETICS INC /WA - Form SC 13G

CUSIP: 812578102

Page 2 of 9

- 1 NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
Capital Guardian Trust Company
- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)
- 3 SEC USE ONLY (b)
- 4 CITIZENSHIP OR PLACE OF ORGANIZATION  
California
- 5 SOLE VOTING POWER  
7,731,530
- 6 SHARED VOTING POWER  
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:  
NONE
- 7 SOLE DISPOSITIVE POWER  
8,902,405
- 8 SHARED DISPOSITIVE POWER  
NONE
- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
8,902,405 Beneficial ownership disclaimed pursuant to Rule 13d-4
- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  
7.8%
- 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
IA BK

Edgar Filing: SEATTLE GENETICS INC /WA - Form SC 13G

CUSIP: 812578102

Page 3 of 9

SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

Schedule 13G  
Under the Securities Exchange Act of 1934

Amendment No.

Item 1(a) Name of Issuer:  
Seattle Genetics Incorporated

Item 1(b) Address of Issuer's Principal Executive Offices:  
21823 30th Drive SE  
Bothell, WA 98021

Item 2(a) Name of Person(s) Filing:  
Capital Group International, Inc. and Capital Guardian Trust  
Company

Item 2(b) Address of Principal Business Office or, if none,  
Residence:  
11100 Santa Monica Blvd.  
Los Angeles, CA 90025

Item 2(c) Citizenship: N/A

Item 2(d) Title of Class of Securities:  
Common Stock

Item 2(e) CUSIP Number:  
812578102

Item 3 If this statement is filed pursuant to sections 240.13d-1(b)  
or 240.13d-2(b) or (c), check whether the person filing is a:  
(b)  Bank as defined in section 3(a)(6) of the Act  
(15 U.S.C. 78c).  
(e)  An investment adviser in accordance with  
section 240.13d-1(b)(1)(ii)(E).  
(g)  A parent holding company or control person in  
accordance with section 240.13d-1(b)(1)(ii)(G).

Item 4 Ownership

Provide the following information regarding the aggregate  
number and percentage of the class of securities of the issuer  
identified in Item 1.

(a) Amount beneficially owned:  
(b) Percent of class:

Edgar Filing: SEATTLE GENETICS INC /WA - Form SC 13G

- (c) Number of shares as to which the person has:
- (i) Sole power to vote or to direct the vote:
- (ii) Shared power to vote or to direct the vote:
- (iii) Sole power to dispose or to direct the disposition of:
- (iv) Shared power to dispose or to direct the disposition of:

See pages 2 and 3

CUSIP: 812578102

Page 4 of 9

Capital Group International, Inc. ("CGII") is the parent holding company of a group of investment management companies that hold investment power and, in some cases, voting power over the securities reported in this Schedule 13G. The investment management companies, which include a "bank" as defined in Section 3(a)(6) of the Securities Exchange Act of 1934 (the "Act") and several investment advisers registered under Section 203 of the Investment Advisers Act of 1940, provide investment advisory and management services for their respective clients which include registered investment companies and institutional accounts. CGII does not have investment power or voting power over any of the securities reported herein. However, by virtue of Rule 13d-3 under the Act, CGII may be deemed to "beneficially own" 12,519,805 shares or 11% of the 113,776,331 shares believed to be outstanding.

Capital Guardian Trust Company ("CGTC"), a bank as defined in Section 3(a)(6) of the Act is deemed to be the beneficial owner of 8,902,405 shares or 7.8% of the 113,776,331 shares believed to be outstanding as a result of its serving as the investment manager of various institutional accounts.

Item 5 Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]

Item 6 Ownership of More than Five Percent on Behalf of Another Person: N/A

Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

1. Capital Guardian Trust Company ("CGTC") is a bank as defined in Section 3(a)(6) of the Act and an investment adviser registered under Section 203 of the Investment Adviser Act of 1940, and a wholly owned subsidiary of Capital Group International, Inc.
2. Capital International Limited ("CIL") does not fall within any of the categories described in Rule 13d-1(b)(ii)(A-F) but its holdings of any reported securities come within the five percent limitation as set forth in a December 15, 1986 no-action letter from the Staff of the Securities and Exchange Commission to The Capital Group Companies, Inc. CIL is a wholly owned subsidiary of Capital Group International, Inc.
3. Capital International Sarl ("CISA") does not fall within any of the categories described in Rule 13d-1(b)(ii)(A-F) but its

Edgar Filing: SEATTLE GENETICS INC /WA - Form SC 13G

holdings of any reported securities come within the five percent limitation as set forth in a December 15, 1986 no-action letter from the Staff of the Securities and Exchange Commission to The Capital Group Companies, Inc. CISA is a wholly owned subsidiary of Capital Group International, Inc. 4. Capital International, Inc. ("CII") is an investment adviser registered under Section 203 of the Investment Advisers Act of 1940 and is a wholly owned subsidiary of Capital Group International, Inc.

CUSIP: 812578102

Page 5 of 9

Item 8 Identification and Classification of Members of the Group:  
N/A

Item 9 Notice of Dissolution of Group: N/A

Item 10 Certification

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: August 10, 2011

Signature: \*\*\*Peter C. Kelly  
Name/Title: Peter C. Kelly, Secretary  
Capital Group International, Inc.

Date: August 10, 2011

Signature: \*Peter C. Kelly  
Name/Title: Peter C. Kelly, Senior Vice President and  
Senior Counsel  
Capital Guardian Trust Company

\*\*\*By /s/ Liliane Corzo  
Liliane Corzo  
Attorney-in-fact

Signed pursuant to a Power of Attorney dated August 1, 2011 included as an Exhibit to Schedule 13G filed with the Securities and Exchange Commission by Capital Group International, Inc.

CUSIP: 812578102

Page 6 of 9

AGREEMENT

Los Angeles, CA

Capital Group International, Inc. ("CGII") and Capital Guardian Trust Company ("CGTC") hereby agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934 (the "Act") in connection with their beneficial ownership of Common Stock issued by Seattle Genetics Incorporated.

CGII and CGTC state that they are each entitled to individually use Schedule 13G pursuant to Rule 13d-1(c) of the Act.

CGII and CGTC are each responsible for the timely filing of the statement and any amendments thereto, and for the completeness and accuracy of the information concerning each of them contained therein but are not responsible for the completeness or accuracy of the information concerning the others.

CAPITAL GROUP INTERNATIONAL, INC.

BY: \*\*\*Peter C. Kelly  
Peter C. Kelly, Secretary  
Capital Group International,  
Inc.

CAPITAL GUARDIAN TRUST COMPANY

BY: \*Peter C. Kelly  
Peter C. Kelly, Senior Vice  
President and Senior Counsel  
Capital Guardian Trust Company

\*\*\*B /s/ Liliane Corzo

Y

Liliane Corzo  
Attorney-in-fact

Signed pursuant to a Power of Attorney dated August 1, 2011 included as an Exhibit to Schedule 13G filed with the Securities and Exchange Commission by Capital Group International, Inc.

CUSIP: 812578102

Page 7 of 9

POWER OF ATTORNEY

The undersigned do hereby appoint Michael J. Downer, Kristine M. Nishiyama and Liliane Corzo, and each of them, acting singly, with full power of substitution, as the true and lawful attorney of the undersigned, to sign on behalf of the undersigned in respect of the ownership of equity securities deemed held by the undersigned, Capital Guardian Trust Company, Capital Group International, Inc., Capital International, Inc., Capital International K.K., Capital International Limited, Capital International Sarl, and Emerging Markets Growth Fund, Inc., and to be reported pursuant to Sections 13(d), 13(f) and 13(g) of the Securities Exchange Act of 1934, as amended, and to execute joint filing agreements with respect to such filings.

IN WITNESS WHEREOF, this Power of Attorney has been executed as of the 1st day of August, 2011.

Capital Group International, Inc.

Capital International  
K.K.

/s/ Peter C. Kelly  
Name: Peter C. Kelly  
Title: Secretary

/s/ Thomas B. Quantrille  
Name: Thomas B.  
Quantrille  
Title: President

Capital Guardian Trust Company

Capital International  
Limited

/s/ Peter C. Kelly  
Name: Peter C. Kelly  
Title: Senior Vice President and Senior  
Counsel

/s/ Ida Levine  
Name: Ida Levine  
Title: Senior Vice  
President

Capital International, Inc.

Capital International  
Sarl



Edgar Filing: SEATTLE GENETICS INC /WA - Form SC 13G

/s/ Peter C. Kelly  
Name: Peter C. Kelly  
Title: Senior Vice President, Senior  
Counsel and Secretary

/s/ Fabrice Remy  
Name: Fabrice Remy  
Title: Vice  
President and Counsel

Emerging Markets Growth Fund, Inc.

CUSIP: 812578102

Page 8 of 9

/s/ Peter C. Kelly  
Name: Peter C. Kelly  
Title: Vice President

CUSIP: 812578102

Page 9 of 9